What records are connected here?
- Evidence lanes
- 3
- Source years
- 6
- Drugs@FDA applications
- 1
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
FDA-approved1,2Evidence: Smaller human trialsInflammation and immune · Muscle
Zilucoplan is a synthetic ring-shaped (macrocyclic) peptide of 15 amino acids that blocks complement protein C5, and the active ingredient in Zilbrysq.1,2 FDA approved Zilbrysq in 2023 for generalized myasthenia gravis in adults who have antibodies against the acetylcholine receptor.1,2 In a 12-week randomized, placebo-controlled trial of 174 adults, it improved daily-function and muscle-strength scores more than placebo. The label carries a boxed warning about serious meningococcal infections.1
| What it is | A complement inhibitor: a 15-amino-acid synthetic macrocyclic peptide that binds complement protein C5, according to the label.1 |
|---|---|
| FDA status | FDA-approved. Drugs@FDA lists Zilbrysq with an original approval date of October 17, 2023. The label has a boxed warning about serious meningococcal infections, and the drug is available only through a restricted program.1,2 |
| Human evidence | One 12-week multicenter, randomized, double-blind, placebo-controlled trial in 174 adults with generalized myasthenia gravis, described in the label.1 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Zilucoplan is a 15-amino-acid synthetic macrocyclic peptide, a peptide whose chain is closed into a ring, that the label classes as a complement inhibitor.1
In the United States it is the active ingredient of Zilbrysq, from UCB, according to Drugs@FDA.2
The label states that zilucoplan binds complement protein C5 and stops it from being split, preventing formation of the terminal complement complex (C5b-9), part of the immune system’s attack machinery.1
The label states that the precise way it helps in myasthenia gravis is unknown but is presumed to involve less C5b-9 deposited where nerves meet muscle.1
The label describes a 12-week randomized, double-blind, placebo-controlled trial in 174 adults with generalized myasthenia gravis; 86 received zilucoplan and 88 placebo, most alongside their existing treatments.1
On the 24-point Myasthenia Gravis Activities of Daily Living scale, scores improved by 4.39 points with zilucoplan and 2.30 with placebo, a difference of 2.09 points, according to the label.1
Muscle-strength scores on the Quantitative Myasthenia Gravis scale also improved more with zilucoplan than with placebo, according to the label.1
Evidence-strength label: Smaller controlled human trials. How this label is assigned
Yes. Drugs@FDA lists Zilbrysq, application NDA 216834, with an original approval date of October 17, 2023.2
The Zilbrysq label cited here (DailyMed SPL version 13, published February 5, 2026) states that it is indicated for generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive.1
The label carries a boxed warning that, as a complement inhibitor, it increases the risk of serious and potentially fatal meningococcal infections, and states that it is available only through a restricted program (Zilbrysq REMS).1
Its precise mechanism in myasthenia gravis, which the label states is unknown.1
Its effect in people without acetylcholine receptor antibodies, who are outside the approved indication in the label.1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Zilucoplan: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Zilucoplan are a bounded selection, not every registration or paper about Zilucoplan. For the years before Zilucoplan was added, PeptideScanner took at most 30 ClinicalTrials.gov registrations that list Zilucoplan as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 30 PubMed papers that name Zilucoplan in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
FDA-approved as Zilbrysq for generalized myasthenia gravis. A 12-week randomized, placebo-controlled trial of 174 adults described in the label found greater improvement in daily-function scores. The label has a boxed warning about serious meningococcal infections.↗↗
Status sources checked through November 15, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
FDA-approved as Zilbrysq for generalized myasthenia gravis. A 12-week randomized, placebo-controlled trial of 174 adults described in the label found greater improvement in daily-function scores. The label has a boxed warning about serious meningococcal infections.↗↗
The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Clinical trials · source date November 5, 2026
ClinicalTrials.gov record NCT06055959↗Added to PeptideScanner November 15, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT06055959↗Source date November 5, 2026Literature metadata · added November 15, 2026
Zilucoplan as a rescue therapy in myasthenic crisis: a case description and summary of early report experiences.↗Source date October 28, 2026Clinical trials · added November 15, 2026
ClinicalTrials.gov record NCT06435312↗Source date October 2, 2026PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
10 of 11 selected trial records include at least one phase value; 11 of 11 include a status value in the retained structured contract.
A phase value is unavailable here for 1 selected record; this is not counted as “no phase.”
11 of 11 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.
PeptideScanner retained ClinicalTrials.gov record NCT04436497 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-07-25, and PeptideScanner's reviewed identity mapping was zilucoplan.
11 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Original-submission application metadata connected by exact reviewed active-ingredient names.
FDA- and HHS-attributed document metadata connected by exact reviewed peptide-name matches, with official GovInfo PDFs.
Selected records span December 20, 2021 to November 5, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06055959 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-11-05, and PeptideScanner's reviewed identity mapping was zilucoplan.↗
Literature metadata
PubMed lists PMID 42467314 in Acta neurologica Belgica as Letter, with publication-date metadata of 2026-07-17 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06435312 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was zilucoplan.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT07215949 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was zilucoplan.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06961747 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-08-27, and PeptideScanner's reviewed identity mapping was zilucoplan.↗
Literature metadata
PubMed lists PMID 42604018 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-07-10 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04297683 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was zilucoplan.↗
Literature metadata
PubMed lists PMID 41314023 in Journal of the neurological sciences as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2025-11-24 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT06471361 at 2026-11-15T21:46:36.651Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was zilucoplan.↗
Literature metadata
PubMed lists PMID 41604997 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-23 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41653661 in Journal of the neurological sciences as Letter, with publication-date metadata of 2026-01-22 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 41058183 in Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG as Case Reports, Journal Article, with publication-date metadata of 2025-10-07 (day precision). PeptideScanner associated the retained record with the identity slug zilucoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026